To further elucidate the effect of SGLT2i on the progression of overall and non-calcified plaque, subgroup analysis of the PSM cohort was conducted based on age (< 65 or ≥ 65 years), sex (male or female), body mass index (< 24 or ≥ 24 kg/m2), hypertension (with or without), current smoker (yes or no), high-sensitivity CRP level (< 1.23 or ≥ 1.23 mmol/L), LDL-C (< 2.27 or ≥ 2.27 mmol/L), and FPG (< 6.1 or ≥ 6.1 mmol/L). Here, CRP is linked to Hypertension.